Neurocrine Biosciences (FRA:NB3) Other Stockholders Equity: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
94 GF Score
Price €152.20
GF Value €165.56
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Other Stockholders Equity?

Neurocrine Biosciences FRA:NB3 -2.56% 94 Other Stockholders Equity is €0 Mil as of Mar. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €165.56 (Fairly Valued). The stock has 6 warning signs investors should review.

Neurocrine Biosciences's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €0 Mil.

Neurocrine Biosciences's quarterly Other Stockholders Equity stayed the same from Sep. 2025 (€0 Mil) to Dec. 2025 (€0 Mil) but then increased from Dec. 2025 (€0 Mil) to Mar. 2026 (€0 Mil).

Neurocrine Biosciences's annual Other Stockholders Equity increased from Dec. 2023 (€-0 Mil) to Dec. 2024 (€0 Mil) but then stayed the same from Dec. 2024 (€0 Mil) to Dec. 2025 (€0 Mil).

Neurocrine Biosciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Other Stockholders Equity Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:NB3
94GF Score
Neurocrine Biosciences Inc FRA:NB3
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0 Mil mean?
Neurocrine Biosciences (FRA:NB3) has a Other Stockholders Equity of €0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Other Stockholders Equity too high?
Neurocrine Biosciences' current Other Stockholders Equity is €0 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Other Stockholders Equity compare to VTRS and ELAN?
Neurocrine Biosciences' Other Stockholders Equity of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Other Stockholders Equity is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €165.56, compared to a current price of €152.20 — trading 8.1% below its estimated fair value. The current Other Stockholders Equity is €0 Mil. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Other Stockholders Equity is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €152.20 is trading 8.1% below its estimated GF Value™ of €165.56. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for FRA:NB3:

  • Other Stockholders Equity: €0 Mil
  • GF Value™: €165.56 vs. price of €152.20 (8.1% below fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for FRA:NB3

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€152.20
Price
€165.56
GF Value